Actively Recruiting

Phase 3
Age: 9Years +
All Genders
NCT07186413

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

Led by Galderma R&D · Updated on 2025-11-21

561

Participants Needed

1

Research Sites

66 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.

CONDITIONS

Official Title

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

Who Can Participate

Age: 9Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female Chinese participants aged 9 years or older at screening.
  • At least 20 inflammatory lesions and 25 non-inflammatory lesions on the face at screening and baseline.
  • Moderate facial acne vulgaris severity (grade 3) on the Investigator Global Assessment scale at screening and baseline.
  • At least 20 inflammatory lesions and 20 to 100 non-inflammatory lesions on the trunk reachable for self-application, at screening and baseline (optional for ages 9 to 11).
  • Moderate acne severity (grade 3) on the Physician's Global Assessment scale on the trunk reachable for self-application, at screening and baseline (optional for ages 9 to 11).
  • Female participants of non-childbearing potential (premenstrual or postmenopausal) meeting specific criteria.
  • Female participants of childbearing potential must have negative pregnancy tests and use approved contraception during the study and for 1 month after last dose.
  • Premenstrual participants starting menses during the study must use approved contraception during the study and 1 month after last dose.
  • Willing and able to comply with all study time commitments and procedures.
  • Understands and signs informed consent at screening before any study procedures.
  • Participants under 18 must have parent/legal representative willing to comply and sign consent; participant must sign assent.
  • At selected sites, agreement to participate in study photographs with appropriate consent.
  • Willing to share personal information according to local privacy regulations.
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women, or women planning pregnancy during study or within 1 month after last dose.
  • Severe or secondary forms of acne at screening and baseline.
  • More than 1 nodule on face or trunk at screening and baseline.
  • Any acne cyst on face or trunk at screening and baseline.
  • Facial or truncal hair, abnormal pigmentation, wounds, scars, or tattoos interfering with assessments.
  • Uncontrolled or serious medical or surgical conditions that may interfere with results or pose risk.
  • Significant abnormal laboratory test results at screening.
  • Known allergies or hypersensitivity to study cream components.
  • Previous participation in any trifarotene cream clinical study.
  • Current or recent participation (within 30 days) in other drug or device trials.
  • Alcohol or drug abuse within 12 months before screening.
  • Inability or unwillingness to undergo multiple blood draws.
  • Significant recent blood loss or donation.
  • Use of prohibited medications or treatments during study.
  • Recent or unwillingness to avoid excessive ultraviolet radiation exposure.
  • Use of drugs that may interfere with acne assessment or worsen acne.
  • Participant vulnerability or inability to consent.
  • More than 1 participant from the same household.
  • Clinical site personnel or close relatives or employees of the sponsor company.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Galderma Research & Development Site #5378

Shanghai, Jing'an District, China

Actively Recruiting

Loading map...

Research Team

G

Galderma Research & Development

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here